Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash Flows From Operating Activities
Net loss	$ (43,653)	$ (18,467)
Adjustments to reconcile net loss to net cash and cash equivalents (used in)/provided by operating activities:
Stock-based compensation	10,862	7,521
Deferred taxes	(13,628)	(8,665)
Depreciation and amortization	44,081	33,568
Acquired in-process research and development ("IPR&D")	1,151	0
Non-cash interest	2,963	1,718
Contingent consideration fair value adjustment	2,134	0
Asset impairment charges	574	0
Gain on sale of ANDAs	(750)	0
Changes in operating assets and liabilities:
Accounts receivable, net	(11,907)	(10,921)
Inventories, net	(14,164)	8,773
Prepaid expenses and other current assets	2,617	1,421
Accounts payable	(5,027)	396
Accrued royalties	360	(2,411)
Current income taxes payable, net	(111)	(6,936)
Accrued government rebates	3,253	3,887
Returned goods reserve	(1,818)	5,091
Accrued expenses, accrued compensation, and other	(3,740)	532
Net Cash and Cash Equivalents (Used in)/Provided by Operating Activities	(26,803)	15,507
Cash Flows From Investing Activities
Acquisition of Novitium Pharma LLC, net of cash acquired	(33)	0
Acquisition of product rights, IPR&D, and other related assets	(7,575)	(21,069)
Acquisition of property and equipment, net	(5,738)	(2,201)
Proceeds from the sale of long-lived assets	750	0
Net Cash and Cash Equivalents Used in Investing Activities	(12,596)	(23,270)
Cash Flows From Financing Activities
Payments on borrowings under credit agreements	(2,250)	(8,034)
Borrowings under Prior Revolver agreement	0	24,000
Series A convertible preferred stock dividends paid	(1,218)	0
Proceeds from stock option exercises and ESPP purchases	690	336
Payments of debt issuance costs	0	(262)
Treasury stock purchases for restricted stock vests	(1,840)	(889)
Net Cash and Cash Equivalents (Used in)/Provided by Financing Activities	(4,618)	15,151
Net Change in Cash and Cash Equivalents	(44,017)	7,388
Cash and cash equivalents, beginning of period	105,301	12,867
Cash and cash equivalents, end of period	61,284	20,255
Reconciliation of cash, cash equivalents, and restricted cash, beginning of period
Cash and cash equivalents	100,300	7,864
Restricted cash	5,001	5,003
Cash and cash equivalents, beginning of period	105,301	12,867
Reconciliation of cash, cash equivalents, and restricted cash, end of period
Cash and cash equivalents	56,281	15,254
Restricted cash	5,003	5,001
Cash and cash equivalents, end of period	61,284	20,255
Supplemental disclosure for cash flow information:
Cash paid for interest, net of amounts capitalized	14,028	5,922
Cash paid for income taxes	156	8,360
Supplemental non-cash investing and financing activities:
Debt issuance costs in accrued expenses	0	81
Acquisition of product rights included in accounts payable	1,000	0
Property and equipment purchased and included in accounts payable	$ 204	$ 28